Figure 2From: Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504) Multivariate probabilistic sensitivity analysis (rresult of 10 000 replications). Arm A: erlotinib followed by docetaxel and gemcitabine (DG); Arm B: DG followed by erlotinib (ICE: incremental cost effectiveness).Back to article page